Print

AVEG 012A/B

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox-GP 160 MN (ALVAC VCP125, HIV-1 GP160 MN) in HIV-1 Uninfected Adults

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) May 19, 1993
ALVAC vCP125 Canarypox Env gp160 B MN
ALVAC vCP125 Viral Vector - Pox
USA 28
NCT00000813
https://clinicaltrials.gov/show/NCT00000813